Clinical trials: High-Risk Cancer, open to volunteers
Smoldering Multiple Myeloma
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
The purpose of this study is to define the natural history of high-risk smoldering myeloma in a modern cohort of patients undergoing close standard of care follow-up with diffusion weighted whole body magnetic resonance imaging.
- Trial name
- SPOTLIGHT (NCT06212323)
- Testing
- Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Utah
High Grade Glioma, Replication Repair Deficient
A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)
This is open label, multicentre, single arm, pilot study of upfront nivolumab in patients with RRD-glioblastoma with favorable immune/genomic biomarkers.
- Trial name
- NCT06519682
- Testing
- Nivolumab, Radiation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Daniel Morgenstern
Prostate Cancer
Registry for Prostate Cancer Focal Therapy
Whole gland therapy (radical prostatectomy and radiotherapy) has been the conventional treatment for localized prostate cancer, but randomized controlled trials have not demonstrated survival benefits compared with watchful…
- Trial name
- NCT07792590
- Testing
- Focal Therapy for Prostate Cancer
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- The University of Hong Kong
Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes
Study of REM-422 in Patients With AML or Higher Risk MDS
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML
- Conditions
- Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory
- Trial name
- NCT06297941
- Testing
- REM-422
- Where
- 9 sites in United States, France
- Volunteers
- 100 people
- Sponsor
- Remix Therapeutics
Uterine Cervical Neoplasms
A Chinese Cohort of Cervical Large Cell Neuroendocrine Carcinoma
Cervical large cell neuroendocrine carcinoma (LCNEC) exhibits highly aggressive biological behavior, including strong invasiveness, a high propensity for metastasis, drug resistance, and poor prognosis, necessitating heightened…
- Trial name
- CN-CLCNEC (NCT07240753)
- Testing
- Postoperative pathological examination confirmed cervical large cell neuroendocrine carcinoma.
- Volunteers
- 200 people
- Sponsor
- Lili
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer
This study aims to evaluate the efficacy and safety of intravenous administration of vedacitinib combined with intravesical instillation of mitomycin in treating patients with high-risk NMIBC with HER2 expression.
- Trial name
- NCT07646145
- Testing
- Disitamab Vedotin, Mitomycin C (MMC)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanxi Province Cancer Hospital
Cervical Dysplasia
The Use of the LuViva Advanced Cervical Scan to Identify Women at High-Risk for Cervical Neoplasia
This study is designed to demonstrate that a multimodal hyperspectral device (LuViva) is able to segregate women with abnormal screening tests into Low and High risk groups for the purpose of determining whether they require…
- Trial name
- NCT04915495
- Testing
- LuViva Advanced Cervical Scan
- Where
- 4 sites in United States
- Volunteers
- 400 people
- Sponsor
- Guided Therapeutics
Non-Small-Cell Lung Cancer
Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression
This is a single-arm, exploratory phase Ib/II study with a seamless design to evaluate the safety and efficacy of Vebreltinib combined with furmonertinib as first-line treatment in patients with locally advanced or metastatic…
- Trial name
- DUAL-THRUST (NCT07655622)
- Testing
- Vebreltinib, Furmonertinib 80mg
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Breast Cancer
High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)
This study is being performed to find out if a new kind of breast imaging (called dedicated breast CT or BCT) can help doctors to see the small structures in breast tissue more clearly.
- Trial name
- LowerDoseBCT (NCT03954431)
- Testing
- Dedicated breast CT(BCT)
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Prostate Cancer
ABlative Radiotherapy (for) Unfavorable Prostate Tumors
Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy…
- Trial name
- ABRUPT (NCT04831983)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Milano Bicocca
Breast Cancer, Chemotherapy Effect
Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
According to the latest data from the World Health Organization's International Agency for Research on Cancer (IARC) for 2020, breast cancer has been the most prevalent cancer with 2.26 million new cases.
- Trial name
- NCT05212454
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
CRC (Colorectal Cancer), Lung Cancer (Diagnosis)
Validation of High-Throughput Large-Format Tissue Preprocessing for Lung and Colorectal Cancer
This project aims to employ a sample preprocessing system in conjunction with three-dimensional imaging techniques to generate morphologically more complete, high-resolution datasets for lung and colorectal cancers.
- Trial name
- NCT07239063
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Colorectal Cancer
Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods
The primary goal is to develop easy accessible diagnostic tools for high risk subjects for colon cancer in different European populations to improve early CRC detection.
- Trial name
- NCT06515821
- Testing
- ONCOSCREEN
- Where
- 8 sites in Bulgaria, France and 4 more
- Volunteers
- 4,100 people
- Sponsor
- Firalis SA
Non-Small Cell Lung Cancer
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally…
- Trial name
- TROPION-Lung10 (NCT06357533)
- Testing
- Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab
- Where
- 290 sites in United States, Australia and 19 more
- Volunteers
- 675 people
- Sponsor
- AstraZeneca
Acute Lymphoblastic Leukemia
Establishment of a Phamacokinetik Model for Erwinase Pharmacokinetiks: The Aim of This Sub Study is to Optimize Target Trough Attainment While Minimizing High Exposures That Impose Increased Risk of Side Effects Such as Hyperammonemia
The aim of this study is to optimize target trough attainment while minimizing high exposures that impose increased risk of side effects such as hyperammonemia.
- Trial name
- NCT07499349
- Testing
- Erwinase PK-model for children and young adults with ALL
- Where
- Denmark
- Volunteers
- 475 people
- Sponsor
- Aarhus University Hospital
RCC, Renal Cell Carcinoma
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
The goal of this clinical trial is to learn about the effects of a higher dose of ncabozantinib in patients with advanced renal cell carcinoma who have progressed on or after receiving cabozantinib treatment.
- Trial name
- NCT05931393
- Testing
- Cabozantinib 80 MG
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Texas Southwestern Medical Center
Neuroendocrine Neoplasm
Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)
This is a phase II, single arm, open-label, multicenter study to evaluate the efficacy and safety of Sintilimab combined with IBI310 and Surufatinib for the treatment of high-grade advanced-neuroendocrine neoplasm
- Trial name
- NESSIE (NCT05165407)
- Testing
- Sintilimab, IBI310, Surufatinib
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Peking University
Acute Myeloid Leukemia
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
This study is a single-center, single-arm, prospective phase II clinical trial evaluating the efficacy and safety of the VAH (Venetoclax and Azacitidine combined with Homoharringtonine) regimen, followed by allo-HSCT for…
- Trial name
- NCT06483906
- Testing
- Venetoclax, Azacitidine and Homoharringtonine
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Pancreatic Neoplasm, Pancreatic Adenocarcinoma
Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Surgical resection is the only potentially curative treatment for patients with pancreatic cancer with the aim of curative R0 resection and related improvement of survival.
- Conditions
- Pancreatic Neoplasm, Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
- Trial name
- STEREOPAC (NCT05083247)
- Testing
- mFOLFIRINOX or Gemcitabine nab-paclitaxel, Isotoxic High-Dose (iHD)-SBRT, Surgery
- Where
- 10 sites in Belgium
- Volunteers
- 256 people
- Sponsor
- Erasme University Hospital
Lung Cancer, Lung Neoplasms
Feasibility and Uptake of Low-Dose CT Lung Cancer Screening in Kuwait
Lung cancer is a leading cause of cancer-related death in Kuwait, where most cases are diagnosed at an advanced stage and there is no national screening program.
- Trial name
- ALIA (NCT07766538)
- Testing
- Low-dose computed tomography (LDCT) lung cancer screening
- Where
- Kuwait
- Volunteers
- 590 people, healthy volunteers welcome
- Sponsor
- Sulaiman Khadadah
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.